Bausch + Lomb Corporation (NYSE:BLCO) on Thursday said it will discontinue development of BL1107 as a topical treatment for glaucoma after the candidate failed to meet the primary endpoint in a Phase 2 clinical trial.
Trial Misses Primary And Key Secondary Endpoints The randomized, double-masked, three-arm, parallel-group Phase 2 study enrolled 159 adults with primary open-angle glaucoma or ocular hypertension.
According to the company, BL1107 did not achieve its primary endpoint of improving visual field mean deviation after 28 days of topical treatment.
Read Also: Activist Investor Seeks Strategic Overhaul At Contact Lens Maker Cooper, Suggests Merger With Bausch + Lomb Key secondary measures of visual function, including low-luminance best-corrected visual acuity responder rates, were also not met.
However, the study showed evidence of ocular target engagement through a reduction in intraocular pressure at Day 28, satisfying one secondary endpoint.
